About: Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry
Creator	Zhang, Xian Ng, Brenner, Erica Colombel, Jean-Frederic Kappelman, Michael Ungaro, Ryan Lewis, Lewis, James Gearry, Richard Kaplan, Ruemmele, Frank Colombel, Zhang Dfaapa, James Ej, Brenner Fe, Underwood Flavio Steinwurz, Fm, Ruemmele Gearry Mbchb, Richard Gg, Kaplan Gilaad, G Jd, Lewis Kaplan, Michele Kissous-Hunt, Michele Kissous-Hunt, Pa-C Md, Kappelman Rahier, J-F Rahier, Jean-Francois Rb, Gearry Rc, Ungaro Reinisch, Walter Sc, Ng Siew, C Underwood, Fox
source	Elsevier; Medline; PMC
abstract	Background and Aims The impact of Coronavirus disease 2019 (COVID-19) on patients with inflammatory bowel disease (IBD) is unknown. We sought to characterize the clinical course of COVID-19 among IBD patients and evaluate the association between demographics, clinical characteristics, and immunosuppressant treatments on COVID-19 outcomes. Methods Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) is a large, international registry created to monitor outcomes of IBD patients with confirmed COVID-19. We calculated age-standardized mortality ratios (SMRs) and utilized multivariable logistic regression to identify factors associated with severe COVID-19, defined as intensive care unit admission, ventilator use, and/or death. Results 525 cases from 33 countries were reported (Median age 43 years, 53% men). Thirty-seven patients (7%) had severe COVID-19, 161 (31%) were hospitalized, and 16 patients died (3% case fatality rate). SMRs for IBD patients were 1.8 (95% confidence interval [CI] 0.9-2.6), 1.5 (95% CI 0.7-2.2), and 1.7 (95% CI 0.9-2.5) relative to data from China, Italy, and the US, respectively. Risk factors for severe COVID-19 among IBD patients included increasing age (adjusted odds ratio [aOR] 1.04, 95% CI 1.01-1.02), ≥2 comorbidities (aOR 2.9, 95% CI 1.1-7.8), systemic corticosteroids (aOR 6.9, 95% CI 2.3-20.5), and sulfasalazine or 5-aminosalicylate use (aOR 3.1, 95% CI 1.3-7.7). TNF antagonist treatment was not associated with severe COVID-19 (aOR 0.9, 95% CI 0.4-2.2). Conclusions Increasing age, comorbidities, and corticosteroids are associated with severe COVID-19 among IBD patients, although a causal relationship cannot be definitively established. Notably, TNF antagonists do not appear to be associated with severe COVID-19.
has issue date	2020-05-18(xsd:dateTime)
bibo:doi	10.1053/j.gastro.2020.05.032
bibo:pmid	32425234
has license	els-covid
sha1sum (hex)	eb98b14541b1182a1b7e34e173a34179af033356
schema:url	https://doi.org/10.1053/j.gastro.2020.05.032
resource representing a document's title	Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry
has PubMed Central identifier	PMC7233252
has PubMed identifier	32425234
schema:publication	Gastroenterology
resource representing a document's body	covid:eb98b14541b1182a1b7e34e173a34179af033356#body_text
is schema:about of	named entity 'Inflammatory' named entity 'Patients' named entity 'Results' named entity 'corticosteroid' named entity 'IBD' named entity 'pneumonia' named entity 'TNF antagonist' named entity 'biologic therapy' named entity 'Diseases' named entity 'TNF' named entity 'comorbidities' named entity 'systemic corticosteroids' named entity 'IBD' named entity 'IBD' named entity 'bacterial infections' named entity 'comorbidities' named entity 'COVID-19' named entity '5-ASA' named entity 'Italy' named entity 'IBD' named entity 'REDCap' named entity 'logistic regression' named entity 'combination therapy' named entity 'IBD' named entity 'autoinflammatory' named entity 'TNF antagonist' named entity 'United States' named entity 'TNF antagonist' named entity 'IBD' named entity 'comorbidities' named entity 'health care providers' named entity '95% CI' named entity 'kidney disease' named entity 'IBD' named entity 'immunosuppressant' named entity 'COVID-19' named entity 'IBD' named entity '8.5' named entity 'TNF inhibitors' named entity 'auto-inflammatory' named entity 'multivariable analysis' named entity '0.9' named entity 'TNF antagonist' named entity 'TNF antagonist' named entity 'COVID-19' named entity 'COVID-19' named entity '5-ASA' named entity 'primary endpoint' named entity 'TNF'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software